[Fundamental and clinical studies on ceftriaxone in the field of obstetrics and gynecology].
Fundamental and clinical studies on ceftriaxone (CTRX, Ro 13-9904) were performed in the field of obstetrics and gynecology and the following results were obtained. The serum concentration was maintained at a high level to remain 22 micrograms/ml about 24 hours after intravenous injection with 1 g CTRX. The level in each tissue except myometrium reached a peak of 50 micrograms/g or higher at 54 minutes after intravenous injection with 1 g CTRX. The peak level in the dead space exudate, obtained 4 to 6 hours after intravenous injection was 77 micrograms/ml with 1 g, and 125 micrograms/ml and 115 micrograms/ml with 2 g. The clinical efficacy was observed in all the cases (excellent in 1 and good in 3) consisting of 1 with Bartholin's abscess, 2 with adnexitis and 1 with pelvioperitonitis. Neither adverse reaction nor posttreatment laboratory test abnormality was observed in any case.
D000328:Adult; D001424:Bacterial Infections / Q000188:drug therapy; D002439:Cefotaxime / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000378:metabolism; D002443:Ceftriaxone; D002584:Cervix Uteri / Q000378:metabolism; D004341:Drug Evaluation; D004717:Endometrium / Q000378:metabolism; D005122:Exudates and Transudates / Q000378:metabolism; D005260:Female; D005831:Genital Diseases, Female / Q000188:drug therapy; D005836:Genitalia, Female / Q000378:metabolism*; D006801:Humans; D007275:Injections, Intravenous; D008875:Middle Aged; D010388:Pelvis / Q000378:metabolism; D014599:Uterus / Q000378:metabolism
D002443:Ceftriaxone; D002439:Cefotaxime